Epstein–Barr-virus-associated hepatitis with aplastic anemia: A case report  

作　　者：Wan-Jun Zhang Li-Qiang Wu Jun Wang Sheng-Yun Lin Bo Wang 

机构地区：[1]Department of Hematology,The First Affiliated Hospital,Zhejiang Chinese Medical University,Hangzhou 310006,Zhejiang Province,China

出　　处：《World Journal of Clinical Cases》2022年第23期8242-8248,共7页世界临床病例杂志

摘　　要：BACKGROUND Hepatitis-associated aplastic anemia(HAAA) is a rare condition. Patients with HAAA usually present with acute hepatitis, jaundice and significantly increased transaminase. After 1–2 mo, hepatitis gradually improves, but progressive hemocytopenia, bone marrow hematopoietic failure, and severe or extremely severe aplastic anemia are manifest. Most cases of HAAA are fulminant and usually lethal if left untreated. The literature on Epstein–Barr virus(EBV)-associated HAAA is sparse.CASE SUMMARY We report a 30-year-old man who was admitted to our hospital because of pale yellow urine and skin with a simultaneous decrease in peripheral blood ternary cells. We made a diagnosis of EBV-associated HAAA. The treatment strategy for this patient included eltrombopag, an immunosuppressive regimen of rabbit antihuman thymocyte immunoglobulin, cyclosporine, and supportive care. The patient was discharged in normal physical condition after five months. A hemogram performed on follow-up revealed that he had achieved a complete response.CONCLUSION Eltrombopag plus anti-thymocyte globubin and cyclosporine may be a therapeutic option for EBV-associated HAAA.Larger studies are warranted to confirm.

关 键 词：Epstein-Barr virus Hepatitis-associated aplastic anemia Immunosuppressive therapy ELTROMBOPAG Case report 

分 类 号：R575.1[医药卫生—消化系统] R556.5[医药卫生—内科学]